The Pharma Data

FEBRUARY 1, 2021

Plegridy is the only approved pegylated interferon for MS with a proven ability to delay the progression of MS disability and reduce relapses. Plegridy was first approved by the FDA in 2014 and is proven to significantly reduce MS relapses, disability progression and brain lesions with a well-understood safety and tolerability profile.

FDA Approval 40

FDA Approval FDA Clinical Trials Biosimilars 40

Broad Institute

APRIL 25, 2024

By Allessandra DiCorato April 25, 2024 As night fell on July 20th, 2014, genomicist Christian Happi was at home with his family in Lagos, Nigeria when he received a phone call he would never forget. On October 20th, 2014, as Ebola continued to spread in Guinea and in neighboring Liberia and Sierra Leone, WHO declared Nigeria free of Ebola.

Virus 132

Virus Hospitals Disease Government 132

Drug Target Review

JANUARY 8, 2024

Jerry has over 30 years of experience in the biopharmaceutical industry and has been involved in the discovery, clinical development, and global commercialisation of more than a dozen FDA-approved drugs with multiple successful exits. acquired by Teva Pharmaceuticals in 2014. a commercial stage pharmaceutical company.

Science 145

Science Disease FDA Approval Pharmaceutical Companies 145

Alta Sciences

FEBRUARY 8, 2024

Utilizing 10 state-of-the-art simulators available in-house at our Montréal clinical facility (with the capacity for more than 20), we are equipped to measure a range of studies; from impairment in cognition and comparing compounds to assessing the impact on new formulations have on impairment.

Clinical Trials 52

Clinical Trials Trials Clinical Pharmacology Clinical Development 52

FDA Law Blog: Biosimilars

AUGUST 12, 2024

Plaintiffs performed the necessary studies on BRAVECTO and filed an NADA on April 8, 2014; FDA approved the NADA on May 15, 2014. In February 2010, an oral formulation of BRAVECTO, a medication to treat and prevent fleas and tick infestation in dogs, was the subject of an INAD submitted to the Agency.

FDA 59

FDA Regulations FDA Approval Production 59

New Drug Approvals

OCTOBER 24, 2023

Molecular Weight: 631.700 FDA APPROVED, To treat moderately to severely active ulcerative colitis in adults, 10/12/2023 Velsipity Etrasimod , sold under the brand name Velsipity , is a medication that is used for the treatment of ulcerative colitis (UC). [1] “FDA Approves New Drug for Ulcerative Colitis” Medscape.

FDA 57

FDA FDA Approval International Pharmacokinetics 57

Drug Target Review

AUGUST 29, 2024

MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs. What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

FDA Law Blog: Biosimilars

FEBRUARY 29, 2024

The use of a surrogate endpoint can considerably shorten the time required prior to receiving FDA approval. If the confirmatory trial shows that the drug actually provides a clinical benefit, then the FDA grants traditional approval for the drug.

FDA 59

FDA Production FDA Approval Compliance 59

The Pharma Data

AUGUST 17, 2021

Second FDA approved indication for dostarlimab in 2021 GARNET study demonstrated objective response rate of 41.6% This indication received accelerated approval based on tumour response rate and durability of response. This approval was based on data from cohort A1, which included 71 patients with dMMR endometrial cancer. [vii]

FDA 52

FDA FDA Approval DNA Treatment 52

The Pharma Data

DECEMBER 18, 2020

Anemia in Chronic Kidney Disease; 2014 [cited 10 December 2020]. Related Articles: Roxadustat FDA Approval History. Contacts For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. References. National Institute of Diabetes and Digestive and Kidney Diseases. .

Disease 52

Disease FDA FDA Approval Science 52

Metabolite Tales Blog

JULY 5, 2023

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. 20 (March 20, 2014). Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

Metabolism of de novo-designed macrocyclic drugs approved by the FDA By Julia Shanu-Wilson To date, only 4% (67) of FDA approved drugs are macrocycles [1]. 20 (March 20, 2014). Current macrocycles in clinical use generally focus on treatment of infectious diseases, cancer and auto-immune disorders.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

The Pharma Data

OCTOBER 15, 2020

John Hospital, researchers compared 649 patients from two cohorts: a recent cohort (2017–2019) from the RECOVER III post-market approval (PMA) study, after the widespread adoption of the best practice of placing Impella pre-PCI, and a cohort from before PMA (2008–2014) when the practice of placing Impella pre-PCI was not yet widely adopted.

Hospitals 52

Hospitals FDA Approval FDA Treatment 52

The Pharma Data

JULY 21, 2021

Bayer also issued a news release earlier today announcing the EC approval. Food and Drug Administration (FDA) approved VERQUVO in the U.S. Since October 2014, Bayer and Merck have pursued a worldwide collaboration in the field of sGC modulators. In January of this year, the U.S.

Treatment 52

Treatment Production Hospitals FDA Approval 52

Agency IQ

JUNE 7, 2024

However, this means that substances that were already available as dietary ingredients prior to their sponsors submitting an IND or obtaining FDA approval may still be marketed as such. L-glutamine offers an example of a more recently approved drug product. FDA’s problems with supplement oversight go well beyond just NDIs.

FDA 40

FDA Science Production FDA Approval 40

The Pharma Data

JANUARY 20, 2021

Esbriet is an oral medicine approved for the treatment of idiopathic pulmonary fibrosis (IPF) and is available in more than 60 countries worldwide. Esbriet was FDA-approved for use in people with IPF in October 2014. Esbriet U.S. Indication. It is not known if Esbriet is safe and effective in children.

FDA 52

FDA Disease Doctors Treatment 52

Codon

AUGUST 26, 2024

Ebola tore through Western Africa in 2014, killing an estimated 11,325 people in two years. After the outbreak ended, it took another three years for the first Ebola vaccine by Merck to be approved. As a result, it is classified as a “drug-free” product and does not require FDA approval.

RNA 87

RNA Virus DNA Vaccine 87

The Pharma Data

JANUARY 18, 2021

This pioneering research led to the clinical development of a humanized anti-VEGF Fab (Ranibizumab, Lucentis ® ), which has also been approved as a therapy for neovascular age-related macular degeneration (AMD), retinal vein occlusion and diabetic macular edema. Enquiries: OKYO Pharma Limited. Gary S. .

Science 40

Science Virus FDA Approval Treatment 40

Drug Discovery World

JULY 13, 2023

The MHRA Early Access to Medicines Scheme (EAMS) was launched in 2014 and aims to give people access to promising new drugs that are not yet licensed for life threatening or severely debilitating conditions when no other treatment is available.

Drugs 237

Drugs Licensing Licensing Regulations 237

The Pharma Data

JUNE 18, 2021

Food and Drug Administration (FDA) has approved PREVNAR 20 (Pneumococcal 20-valent Conjugate Vaccine) for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes in the vaccine in adults ages 18 years and older. Following today’s FDA approval, the U.S.

Vaccine 52

Vaccine FDA Approval FDA Disease 52

NIH Director's Blog: Drug Development

JUNE 14, 2016

That’s critical considering that just 1 in 10 drug candidates entering human clinical trials successfully goes on to receive FDA approval [5]. 2014 Jan;32(1):40-51. 2012 Jul 6;337(6090):100-104. [4] 4] Victoza® significantly reduced the risk of major adverse cardiovascular events in the LEADER Trial. Novo Nordisk.

Drugs 52

Drugs Disease Drug Development Clinical Trials 52

The Pharma Data

NOVEMBER 5, 2020

BRILINTA is approved in more than 110 countries for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (ACS) and in more than 70 countries for the secondary prevention of cardiovascular events among patients who are at high-risk and have experienced a heart attack. Lancet Neurol 2014; 13(2):178–94.

Disease 40

Disease Trials Therapies Treatment 40

FDA Law Blog: Biosimilars

FEBRUARY 27, 2024

156, a patent may be extended only once (even if it would be eligible for extension on more than one occasion because it applies to several FDA-approved products), and only one patent may be extended for each regulatory review period. In September 2014—nearly ten years ago!—PTE To that end, 35 U.S.C. § 156(c)(4)

FDA Approval 59

FDA Approval FDA Production Therapies 59

The Pharma Data

AUGUST 31, 2020

Food and Drug Administration (FDA) approval for the cobas® HIV-1/HIV-2 Qualitative Test for use on the fully automated cobas® 6800/8800 Systems in the U.S. Published 2014 Aug 26. Combines confirmatory HIV testing and HIV-1/HIV-2 differentiation into one single test. Clin Infect Dis. 2011;52(6):780-787. BMC Infect Dis.

FDA Approval 52

FDA Approval FDA Virus Disease 52

The Pharma Data

JANUARY 27, 2021

Our objective is to work with Bruker and our clinical partners to deliver an effective and high throughput assay protocol, that can be applied in the clinical setting, with the required sensitivity and specificity and CE/FDA approvals to provide a useful additional diagnostic tool in the fight against the coronavirus. Source link.

Laboratories 52

Laboratories FDA Approval Hospitals Regulations 52

Drug Discovery World

JANUARY 17, 2024

Moreover, NGS testing is being used in three main clinical circumstances, including: (i) the determination of patient eligibility for clinical trials, (ii) for guiding advanced refractory disease treatment when first line treatments have failed, and (iii) for off-label use of FDA-approved drugs. Cancer Research UK [link] (2014).

DNA 147

DNA Clinical Trials RNA Treatment 147

The Pharma Data

OCTOBER 27, 2021

The primary endpoint is complete response rate (CRR) grounded on stylish response by central review (Lugano 2014 criteria). This transnational trial has enrolled cases from over 30 spots in 12 countries worldwide. After infusion, complaint assessments were performed every three months.

FDA 52

FDA Trials Treatment FDA Approval 52

Broad Institute

OCTOBER 11, 2023

As a first step, Manguso set his sights on treatments called PD-1 checkpoint inhibitors, which at the time had shown tremendous promise in clinical trials and would receive their first FDA approval in 2014.

Research 137

Research Immune Response Clinical Trials Cell Biology 137

The Pharma Data

AUGUST 17, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. On March 25, 2011, the U.S.

Treatment 52

Treatment Immune Response Trials FDA Approval 52

The Pharma Data

SEPTEMBER 8, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China. On March 25, 2011, the U.S.

Research 52

Research Immune Response Treatment Trials 52

Agency IQ

JUNE 2, 2023

These prototypes, and the intended form and function of a PMI for prescription drugs, were further refined in a series of workshops with the Brookings Institute between 2010 and 2014. Curiously, there is no direction for the patient to seek out the full FDA-approved labeling.

FDA 40

FDA FDA Approval Production Regulations 40

Agency IQ

APRIL 26, 2024

Sponsors should submit a completed copy of Form FDA 2253, plus any “specimens of mailing pieces and any other labeling or advertising devised for promotion of the reference product or biosimilar product” at the time of its initial publication or dissemination. Yes, the guidance confirms.

Biosimilars 40

Biosimilars Science FDA Licensing 40

Agency IQ

MARCH 25, 2024

FDA addressed the expanding practice of drug compounding in 1992 by issuing a compliance policy guide that clarified that pharmacies which compounded products at certain scales, for certain purposes, or without FDA approval were clearly operating “outside the bounds of traditional pharmacy practice.”

FDA 40

FDA Pharmacy Production Drugs 40

The Pharma Data

DECEMBER 21, 2020

With seven new medicines launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, the Company is committed to advance oncology as a key growth driver for AstraZeneca focused on lung, ovarian, breast and blood cancers. Related Articles: Tagrisso (osimertinib) FDA Approval History.

Treatment 52

Treatment Trials Disease FDA 52

The Pharma Data

APRIL 11, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China.

Trials 52

Trials Treatment Immune Response Clinical Trials 52

The Pharma Data

JUNE 18, 2021

” The pivotal Phase 3 RESONATE-2 study served as the basis for the FDA approval of IMBRUVICA as a single-agent in first-line treatment for CLL/SLL in 2016, following initial approval for relapsed/refractory (R/R) patients in 2014 based on the RESONATE study. volume 4, Article number: 4782 (2014).

FDA Approval 40

FDA Approval Treatment FDA Therapies 40

The Pharma Data

JUNE 30, 2021

In July 2014, Opdivo was the first PD-1 immune checkpoint inhibitor to receive regulatory approval anywhere in the world. Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China.

Treatment 52

Treatment Trials FDA Approval Disease 52